1.. Coronavirus disease 2019 {#s0001}
============================

The SARS-CoV-2 virus is spreading on a rapid scale around the globe, causing COVID-19 and thus the breakdown of human activity and the global economy due to lockdowns. Citing the alarming levels of COVID-19 spread and its severity, WHO has declared a global emergency on 30 January 2020. The incubation period for COVID-19 ranges from 2--14 days, with an average of 5 days. The majority of patients (\~80%) exhibit mild or moderate symptoms while about 14% are severe infections (requiring oxygen therapy) and about 5% are critical infections, ultimately develops acute respiratory distress syndrome (ARDS), sepsis, and multi-organ failure \[[@cit0001],[@cit0002]\]. Symptomatic management of disease and oxygen therapy has remained the mainstay of clinical treatment, in absence of any specifically approved treatment for COVID-19. Until, vaccine development is ongoing to establish the herd immunity, but testing and development of vaccines may likely take a year. Additionally, several known antiviral drugs are being actively repurposed for the treatment of COVID-19 but none of them are specifically approved yet. Apart from this, many approaches that directly block the viral entry and even immunopathology based treatment strategies are of major interest. However, rapid mutations resulting in the new pathogenic strains of SARS-CoV-2 that develop an urgent need for suitable therapeutic strategies \[[@cit0003]\]. The infection can be transmitted mainly via inhalation of aerosol droplets from coughing, sneezing, or talking of symptomatic and asymptomatic individuals. Inhaled SARS-CoV-2 first binds to the nasal epithelium and starts replication where SARS-CoV-2 entry factors (entry receptor angiotensin-converting enzyme 2 (ACE2) and entry-associated protease (TMPRSS2)) are highly expressed together with innate immune genes \[[@cit0004],[@cit0005]\]. Then SARS-CoV-2 reaches the alveolar space of the lung and infects alveolar type II cells, rich in the ACE2 receptor \[[@cit0006]\]. Similar to SARS-CoV and MERS infection, patients with COVID-19 show clinical manifestations including fever, nonproductive cough, difficulty in breathing, and severe lung pathology leading to death \[[@cit0007]\]. Currently, there is no drug or vaccine available for COVID-19 and further, because of mutation in new strains of SARS-CoV-2 along with patient-derived mutations \[[@cit0008]\], it becomes more difficult to treat SARS-CoV-2 infection. In this situation, several available host-directed therapies might play as a potential approach to combat ongoing pandemic COVID-19 \[[@cit0009]\].

2.. Expert opinion {#s0002}
==================

Lymphopenia is a common feature in patients with severe COVID-19, with drastically reduced numbers of CD4^+^, CD8^+^ T cells, B cells and natural killer (NK) cells, and reduced percentage of monocytes, eosinophils, and basophils \[[@cit0002],[@cit0006]\]. It has been found that COVID-19 patients have very low levels of NK cells in their blood \[[@cit0010]\]. Taking lower levels of NK cells into consideration, researchers at Seattle Research Institute in collaboration with Celularity (cell therapeutics company), USA are trying out a potential new therapy, infusing patients with NK cells (CYNK-001), which would be very helpful for combating the virus (NCT04365101). Therefore providing patients with effective supplements of NK cells may help thwart the disease more efficiently. Additionally, isolation and short term expansion of SARS-CoV-2 specific T cells and their use as the cellular drug could be an efficient treatment option for COVID-19.

In most severe patients, the SARS-CoV-2 infection is associated with a lethal immuno-pathological event termed as 'cytokine storm', which can be characterized as increased plasma concentration of cytokines like IL-6, IL-1, IL-2, IL-8, IL-17, G-CSF, GM-CSF, IP10, MCP1, MIP1α and TNFα \[[@cit0001],[@cit0011]--[@cit0013]\]. From a recent meta-analysis, IL-6 levels reported three-fold higher in COVID-19 patients that requiring ICU care and suggested clinical indicators disease severity \[[@cit0014]\]. A multicenter, randomized clinical study has been conducted, to evaluate the efficacy and safety of tocilizumab (IL-6 receptor-targeted monoclonal antibody), and reported a quick recovery in clinical symptoms in 21 severe COVID-19 patients (ChiCTR2000029765). Similarly, anti-TNFα antibodies like infliximab or adalimumab, have a well-established safety profile and maybe a potentially effective therapy to treat COVID-19. The blockage of IL-17 might also prove beneficial in COVID-19 patients as it has been shown promising involvement in chronic inflammation \[[@cit0015]\] and could be further investigated.

Interestingly, SARS-CoV-2 showed a high replication rate and a lower induction of host interferon in human lungs when compared to SARS-CoV \[[@cit0016]\]. Further, it has been reported that deficiency or low activity of type-I interferon (IFN) is associated with high blood viral load of SARS-CoV-2 in COVID-19 patients and inversely related to the NFĸB-driven inflammatory response that results in increased levels of IL-6 and TNF-α \[[@cit0017]\]. Based on the evidence, direct administration of IFN and anti-inflammatory host-directed therapies targeting IL-6 and TNF-α might potentially reduce the severe disease symptoms in COVID-19 patients, thus have been suggested for urgent trials \[[@cit0018],[@cit0019]\].

Host-directed therapies using mesenchymal stem cells (MSCs) have been shown to prevent the cytokine storm and repair pulmonary cell damage by promoting alveolar fluid clearance in COVID-19 patients \[[@cit0020]\]. A recent study, based on MSC transplantation in COVID-19 patients, has shown significant improvement in clinical symptoms of all the patients \[[@cit0021]\].

In severe condition, COVID-19 develops ARDS which leads to the thrombosis, anti-inflammatory function of endothelial cells, coagulopathy, complement in platelet activation, and ultimately disseminated intravascular coagulation (DIC) syndrome \[[@cit0022]\]. In this effect, anticoagulant therapy, primarily by low molecular weight heparin (LMWH) has been reported with a decreased mortality in COVID-19 patients \[[@cit0023]\]. Similarly, eculizumab, a human monoclonal antibody that designed to bind and inhibit terminal complement protein C5, is being investigated in a cohort multiple randomized controlled trials (cmRCT) (NCT04346797 and NCT04355494).

Additionally, vascular leakage and pulmonary edema are also common in severe COVID-19 patients. A clinical trial (NCT04342897) revealing the circulating levels of angiopoietin 2 and its correlation with pulmonary edema and mortality in ARDS associated COVID-19 patients that might be a potential host-directed therapy. Further, bevacizumab, a monoclonal anti-VEGF antibody that binds to VEGF and neutralizes its vessel-permeabilizing effect in COVID-19 patients is also under clinical trials (NCT04344782, NCT04275414, and NCT04305106). Host-directed therapies using LMWH, fondaparinux, betrixaban, and rivaroxaban have been suggested at prophylaxis doses in DIC associated COVID-19 patients \[[@cit0024],[@cit0025]\].

Anti-inflammatory drugs are another potential option that has been reported as efficient candidates for host-directed therapies in infectious diseases \[[@cit0026],[@cit0027]\]. A timely anti-inflammatory treatment initiated at the right time might helpful in COVID-19 management and can also be designed for the individual patient \[[@cit0028]\]. Dexamethasone, an anti-inflammatory corticosteroid, recently, reported having protective outcomes in COVID-19 patients with ARDS in a multicentre, randomized, controlled clinical trial \[[@cit0029],[@cit0030]\]. Further, FDA approved drugs including baricitinib, fedratinib, and ruxolitinib, are janus kinase inhibitors and suggested as potential drugs for the treatment of COVID-19 \[[@cit0031],[@cit0032]\]. Being strong anti-inflammatory and suppose to reduce the consequences of enhanced levels of cytokines, these drugs might be used as potential host-directed therapy for COVID-19.

In conclusion, host-directed therapies ([Figure 1](#f0001){ref-type="fig"}) may serve a strategic better option to treat COVID-19 when there is no specific drug or vaccine available at present. Figure 1.Different host-directed therapies for the treatment of COVID-19.
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